一次情報の記録
決定級トップライン結果
MIRA Pharmaceuticals Reports Positive MIRA-55 Chronic Inflammatory Pain Preclinical Study
MIRA-55は、慢性炎症性疼痛の21日間CFAラットモデルにおいて、セレコキシブと同等の機械的および熱的疼痛過敏の統計的に有意な軽減（p<0.001）を示し、持続的な有効性、耐容性の欠如、腫脹の減少、および両性での良好な忍容性を示しました。これらの肯定的なIND申請支援結果は、IND提出に向けた進展を裏付けています。
主要事実
出典の抜粋
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable Tolerability MIAMI, Oct. 22 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced positive results from a 21-day preclinical proof-of-concept study evaluating oral MIRA-55 in a validated model of chronic inflammatory pain. The results support the continued advancement of MIRA-55 towa